Burns J W & Co. Inc. NY Sells 467 Shares of Zoetis Inc. (NYSE:ZTS)

Burns J W & Co. Inc. NY lessened its stake in Zoetis Inc. (NYSE:ZTS) by 1.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,158 shares of the company’s stock after selling 467 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Zoetis were worth $5,272,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Blue Bell Private Wealth Management LLC lifted its holdings in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares in the last quarter. Webster Bank N. A. raised its position in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the last quarter. Independence Bank of Kentucky lifted its stake in shares of Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after acquiring an additional 130 shares during the period. Private Wealth Management Group LLC bought a new position in Zoetis in the fourth quarter valued at about $33,000. Finally, Ramirez Asset Management Inc. acquired a new stake in Zoetis in the third quarter worth about $35,000. 92.80% of the stock is owned by institutional investors.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the sale, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Down 1.8 %

NYSE ZTS traded down $3.10 during trading hours on Friday, reaching $173.36. 4,189,580 shares of the company’s stock were exchanged, compared to its average volume of 2,374,760. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The company has a market capitalization of $79.10 billion, a price-to-earnings ratio of 33.40, a price-to-earnings-growth ratio of 2.74 and a beta of 0.88. The company’s 50-day moving average is $168.69 and its two-hundred day moving average is $178.81. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.04. The company had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.31 earnings per share. On average, analysts forecast that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is currently 33.33%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ZTS shares. Stifel Nicolaus reduced their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. The Goldman Sachs Group dropped their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Barclays reduced their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Finally, HSBC dropped their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $211.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.